Built to Tackle Neurodegenerative Diseases

David is a co-founder and director of Integra Advisory, with over 20 years of experience advising companies and in senior management positions. He has managed a significant number of initial public offers, secondary capital raisings, mergers and acquisition transactions as part of developing and maintaining long-term relationships with clients. David has also held a number of senior management positions (including CEO), giving him a management and client perspective of capital raisings, M&A transactions, strategic advice and stakeholder/investor relations. Prior to establishing Integra Advisory, David spent 18 years at Wilson HTM, where he held several senior positions, including Chief Executive Officer.

Alan was the CEO and MD of Pharmaxis Ltd for 14 years, responsible for raising more than $350 million in the U.S., Europe and Australia. In that role he oversaw the development to Marketing Authorisation of a new inhaled dry powder treatment for cystic fibrosis (Bronchitol) and a bronchial challenge test for hyperactive airway disease (Aridol). He built a drug discovery capability within Pharmaxis and participated in the creation of PXS4728 — now licensed to Boehringer Ingelheim for the treatment of NASH. Previously, he was the CEO of Promics Ltd (now part of Teva) and developed the first C5a receptor antagonist to patients with rheumatoid arthritis. While head of drug discovery at Kinacia, he invented KN-309, a PI3 kinase inhibitor (subsequently licensed to AstraZeneca). He is a former member of the scientific advisory board of Xenome Limited, a former Non-Executive Director of Patrys Limited and is a current Non-Executive Director of Infensa Bioscience Ltd and Chairman of AllVascular Ltd. While in the UK, as a Senior Scientist at Wellcome PLC (now GSK), he invented the anti-migraine drug Zomig.

Steven possesses over twenty years' executive management and investment banking experience across North America (New York), Europe (London) and Asia Pacific (Hong Kong / Sydney). During his career, Steven has advised on a broad range of listed and unlisted mergers, divestments, acquisitions, strategic reviews, restructurings and capital raisings within Healthcare. Previously Steven was Managing Director and Head of Asia for Healthcare at Barclays Investment Bank and the former Chief Strategy Officer and Acting Chief Financial Officer of Estia Health. He is currently the Head of Healthcare and M&A at Ord Minnett.

A/Prof Woodruff is an ARC Future Fellow conducting research into the innate immune system in the brain, with specific research revolving around the Complement System. A focus of his work has been the chronic neurodegenerative diseases amyotrophic lateral sclerosis, Huntington's disease and Parkinson's disease, as well as maintaining an active interest in Alzheimer's disease. In 2010, A/Prof Woodruff started his own group and independent laboratory at the University of Queensland.

Alan has experience in corporate reorganisation and M&A. He was the previous Chairman and Managing Director of Progen Industries for 11 years, including listing on the ASX and completing a direct NASDAQ cross listing. More recently, he was the Managing Director of Promics Pty Ltd and executed a trade sale to Cephalon/Teva. Currently, he is the CEO of Biosecurity/Opti Grow.

Paul has over 25 years of business development experience across a range of disease areas, including CNS disorders, and a deep network in the global biopharmaceutical industry. His current roles include business development manager at BioCurate, established in 2017 by Monash University and the University of Melbourne to commercialise drug discoveries in their two institutions. He was previously the life sciences specialist at Austrade, the Australian Government’s investment promotion agency, where he facilitated foreign direct investment into Australian research in infectious diseases, autoimmune diseases, neurodegenerative diseases, cancer and other therapeutic areas. Earlier, Paul was the founder and Executive Chairman of Bio-Link, a privately-owned biotechnology business development company with a range of clients across Australia.